# Verastem Oncology Prices $250 Million Through Stock and Warrant Offering

- URL: https://stocks.freetheai.org/news/verastem-oncology-prices-250-million-through-stock-and-warrant-offering-4ed9e0
- Published: 2026-10-14T10:04:00Z
- Category: company_news; sentiment: bearish; impact: medium
- Symbols: [NASDAQ:VSTM](https://stocks.freetheai.org/symbols/NASDAQ-VSTM)
- Written by our AI from expert market sources across the web for FreeTheAI Stocks, built by Vibhek Soni
- How write-ups are made: https://stocks.freetheai.org/how-we-write
- Not financial advice: https://stocks.freetheai.org/disclaimer

Verastem Oncology (NASDAQ:VSTM) has priced an underwritten public offering to raise approximately $250 million in gross proceeds. The capital raise includes 30,937,500 common shares priced at $8.00 per share alongside pre-funded warrants for up to 312,503 shares at $7.9999 each. All securities in the transaction are primary shares, meaning all net funds will flow directly to the company.

The pricing created immediate pressure on the biopharmaceutical company's stock, which fell 9.70% to $7.45. Equity offerings often dilute existing shareholders and set a short-term price benchmark, which pushed trading below the offering price. However, the transaction eliminates short-term financing concerns for the clinical-stage biopharma developer by securing primary funds for its research and development pipeline, including VS-7375, as well as general working capital.

Looking ahead, the transaction is expected to close on or around October 15, 2026, subject to standard closing conditions. With capital secured for its ongoing programs, investors will likely focus on future clinical data, regulatory updates, and potential partnership developments as the primary drivers for the company's long-term valuation.

## Key points

- Verastem Oncology priced an offering of 30,937,500 shares at $8.00 per share and 312,503 pre-funded warrants at $7.9999.
- The share sale will generate approximately $250 million in gross primary proceeds for the biopharmaceutical firm.
- Net proceeds are designated for research and development on VS-7375 as well as general working capital.
- Shares of Verastem fell 9.70% to $7.45 following the pricing of the equity offering.
- The offering is scheduled to close on or about October 15, 2026, pending customary conditions.

## Questions and answers

### How much money is Verastem Oncology raising in its stock offering?

Verastem Oncology is raising approximately $250 million in gross proceeds through an offering of 30,937,500 common shares and 312,503 pre-funded warrants.

### What will Verastem Oncology use the offering proceeds for?

The company plans to use the gross proceeds to support working capital and fund research and development for its drug candidate VS-7375.

### When will Verastem's stock offering close?

The transaction is expected to close on or about October 15, 2026, subject to customary closing conditions.